COLUMN GROUP II, LP 4
4 · Oric Pharmaceuticals, Inc. · Filed Apr 28, 2020
Insider Transaction Report
Form 4
COLUMN GROUP II, LP
10% Owner
Transactions
- Conversion
Common Stock
2020-04-28+3,500,000→ 3,575,000 total - Conversion
Series A Preferred Stock
2020-04-28−3,500,000→ 0 total→ Common Stock (3,500,000 underlying) - Conversion
Series B Preferred Stock
2020-04-28−625,000→ 0 total→ Common Stock (625,000 underlying) - Conversion
Series D Preferred Stock
2020-04-28−151,515→ 0 total→ Common Stock (151,515 underlying) - Conversion
Common Stock
2020-04-28+625,000→ 4,200,000 total - Conversion
Common Stock
2020-04-28+416,666→ 4,616,666 total - Conversion
Common Stock
2020-04-28+151,515→ 4,768,181 total - Conversion
Series C Preferred Stock
2020-04-28−416,666→ 0 total→ Common Stock (416,666 underlying)
Footnotes (2)
- [F1]Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.
- [F2]The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.